Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice.

Abstract

Epigallocatechin-3-gallate (EGCG), a catechin found in green tea, has been previously investigated for its neuroprotective effects in vitro and in vivo. In the present study, we aimed to evaluate its possible beneficial effects in a well-established preclinical mixed model of familial Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) based on the use of transgenic APPswe/PS1dE9 (APP/PS1) mice fed with a high fat diet (HFD). C57BL/6 wild-type (WT) and APP/PS1 mice were used in this study. APP/PS1 mice were fed with a palmitic acid-enriched HFD (APP/PS1 HFD) containing 45% of fat mainly from hydrogenated coconut oil. Intraperitoneal glucose tolerance tests (IP-GTT) and insulin tolerance tests (IP-ITT) were performed. Western blot analyses were performed to analyse protein expression, and water maze and novel object recognition test were done to evaluate the cognitive process. EGCG treatment improves peripheral parameters such as insulin sensitivity or liver insulin pathway signalling, as well as central memory deficits. It also markedly increased synaptic markers and cAMP response element binding (CREB) phosphorylation rates, as a consequence of a decrease in the unfolded protein response (UPR) activation through the reduction in the activation factor 4 (ATF4) levels and posterior downregulation of protein tyrosine phosphatase 1B (PTP1B). Moreover, EGCG significantly decreased brain amyloid β (Aβ) production and plaque burden by increasing the levels of α-secretase (ADAM10). Also, it led to a reduction in neuroinflammation, as suggested by the decrease in astrocyte reactivity and toll-like receptor 4 (TLR4) levels. Collectively, evidence suggests that chronic EGCG prevents distinct neuropathological AD-related hallmarks. This study also provides novel insights into the metabolic and neurobiological mechanisms of EGCG against cognitive loss through its effects on UPR function, suggesting that this compound may be a promising disease-modifying treatment for neurodegenerative diseases.

• Authors: Miren Ettcheto, Amanda Cano, Patricia R Manzine, Oriol Busquets, Ester Verdaguer, Rubén Dario Castro-Torres, Maria Luisa García, Carlos Beas-Zarate, Jordi Olloquequi, Carme Auladell, Jaume Folch, Antoni Camins
• Journal: Molecular neurobiology (Mol Neurobiol) Vol. 57 Issue 4 Pg. 1814-1827 (Apr 2020) ISSN: 1559-1182 [Electronic] United States
• PMID: 31838720 (Publication Type: Journal Article)

Chemical References

• Amyloid beta-Peptides
• Blood Glucose
• Insulin
• Presenilin-1
• Catechin
• epigallocatechin gallate

Topics

• Amyloid beta-Peptides (metabolism)
• Animals
• Blood Glucose (metabolism)
• Catechin (analogs & derivatives, chemistry, pharmacokinetics, pharmacology, therapeutic use)
• Cognitive Dysfunction (blood, complications, drug therapy, physiopathology)
• Diet, High-Fat
• Hippocampus (drug effects, pathology, physiopathology)
• Insulin (metabolism)
• Liver (metabolism)
• Male
• Memory Disorders (blood, complications, drug therapy, physiopathology)
• Mice, Inbred C57BL
• Mice, Obese
• Mice, Transgenic
• Models, Biological
• Presenilin-1 (metabolism)
• Signal Transduction
• Spatial Learning (drug effects)
• Tissue Distribution (drug effects)
• Unfolded Protein Response (drug effects)